Literature DB >> 34072923

Cord-Blood-Derived Professional Antigen-Presenting Cells: Functions and Applications in Current and Prospective Cell Therapies.

Sarah Cunningham1, Holger Hackstein1.   

Abstract

Human umbilical cord blood (UCB) represents a valuable source of hematopoietic stem cells, particularly for patients lacking a matching donor. UCB provides practical advantages, including a lower risk of graft-versus-host-disease and permissive human leukocyte antigen mismatching. These advantageous properties have so far been applied for stem cell, mesenchymal stromal cell, and chimeric antigen receptor T cell therapies. However, UCB-derived professional antigen-presenting cells are increasingly being utilized in the context of immune tolerance and regenerative therapy. Here, we review the cell-specific characteristics as well as recent advancements in UCB-based cell therapies focusing on dendritic cells, monocytes, B lymphocytes, innate lymphoid cells, and macrophages.

Entities:  

Keywords:  antigen presentation; cell therapy; immune reconstitution; umbilical cord blood

Year:  2021        PMID: 34072923     DOI: 10.3390/ijms22115923

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  181 in total

1.  Mesenchymal progenitor cells in human umbilical cord blood.

Authors:  A Erices; P Conget; J J Minguell
Journal:  Br J Haematol       Date:  2000-04       Impact factor: 6.998

2.  Therapeutic benefit of treatment of stroke with simvastatin and human umbilical cord blood cells: neurogenesis, synaptic plasticity, and axon growth.

Authors:  Xu Cui; Michael Chopp; Amjad Shehadah; Alex Zacharek; Nicole Kuzmin-Nichols; Cyndy Davis Sanberg; Junhao Dai; Chunling Zhang; Yuji Ueno; Cynthia Roberts; Jieli Chen
Journal:  Cell Transplant       Date:  2012-03-08       Impact factor: 4.064

Review 3.  Neonatal adaptive immunity comes of age.

Authors:  Becky Adkins; Claude Leclerc; Stuart Marshall-Clarke
Journal:  Nat Rev Immunol       Date:  2004-07       Impact factor: 53.106

4.  Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages.

Authors:  D Niederwieser; M Herold; W Woloszczuk; W Aulitzky; B Meister; H Tilg; G Gastl; R Bowden; C Huber
Journal:  Transplantation       Date:  1990-10       Impact factor: 4.939

5.  High expression of Fas ligand on cord blood dendritic cells: a possible immunoregulatory mechanism after cord blood transplantation.

Authors:  N Naderi; S M Moazzeni; A A Pourfathollah; K Alimoghaddam
Journal:  Transplant Proc       Date:  2011-12       Impact factor: 1.066

6.  Impaired responses to toll-like receptor 4 and toll-like receptor 3 ligands in human cord blood.

Authors:  Dominique De Wit; Sandrine Tonon; Véronique Olislagers; Stanislas Goriely; Michaël Boutriaux; Michel Goldman; Fabienne Willems
Journal:  J Autoimmun       Date:  2003-11       Impact factor: 7.094

Review 7.  Impact of HLA in cord blood transplantation outcomes.

Authors:  A Ruggeri; A Paviglianiti; E Gluckman; V Rocha
Journal:  HLA       Date:  2016-04-06       Impact factor: 4.513

8.  Neonatal innate TLR-mediated responses are distinct from those of adults.

Authors:  Tobias R Kollmann; Juliet Crabtree; Annie Rein-Weston; Darren Blimkie; Francis Thommai; Xiu Yu Wang; Pascal M Lavoie; Jeff Furlong; Edgardo S Fortuno; Adeline M Hajjar; Natalie R Hawkins; Steven G Self; Christopher B Wilson
Journal:  J Immunol       Date:  2009-11-16       Impact factor: 5.422

9.  Human b1 cell frequency: isolation and analysis of human b1 cells.

Authors:  Daniel O Griffin; Thomas L Rothstein
Journal:  Front Immunol       Date:  2012-05-25       Impact factor: 7.561

Review 10.  Macrophage Modification Strategies for Efficient Cell Therapy.

Authors:  Anastasiya S Poltavets; Polina A Vishnyakova; Andrey V Elchaninov; Gennady T Sukhikh; Timur Kh Fatkhudinov
Journal:  Cells       Date:  2020-06-24       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.